Supplementary Table 2:
Distribution of sample characteristics according to diagnoses of obstructive sleep apnea (on the left) and periodic limb movement disorder (on the right)
| Characteristic | Raised AHI (N=242; P=59.75%) |
Normal AHI (N=163; P=40.45%) |
p | High PLMI (N=165; P=40.74%) |
Normal PLMI (N=240; P=59.51%) |
p |
|---|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | |||
| Age (in years) | 49.08 (13.80) | 40.80 (12.75) | <0.001 | 49.70 (14.37) | 43.03 (13.05) | <0.001 |
| NC (in cm) | 42.04 (4.27) | 38.00 (4.22) | <0.001 | 40.97 (4.75) | 40.03 (4.57) | 0.104 |
| BMI | 36.47 (8.10) | 31.56 (6.77) | <0.001 | 34.30 (7.90) | 34.64 (8.01) | 0.525 |
| ESS Score | 11.15 (5.24) | 10.59 (5.50) | 0.344 | 10.05 (5.46) | 11.52 (5.19) | 0.004 |
| N (valid %) | N (valid %) | N (valid %) | N (valid %) | |||
| Male Sex | 115 (47.52) | 50 (30.67) | 0.001 | 74 (44.85) | 91 (37.92) | 0.163 |
| Tobacco Use | 89 (37.24) | 71 (44.65) | 0.139 | 62 (37.80) | 98 (41.88) | 0.414 |
| Alcohol Use | 30 (12.50) | 21 (13.21) | 0.836 | 17 (10.37) | 34 (14.47) | 0.227 |
| Caffeine Use | 194 (83.26) | 127 (81.94) | 0.735 | 134 (82.72) | 187 (82.74) | 0.994 |
| Medical History | ||||||
| Psychiatric | 170 (71.73) | 134 (83.23) | 0.008 | 123 (75.46) | 181 (77.02) | 0.718 |
| Cardiovascular | 148 (62.45) | 68 (42.24) | <0.001 | 102 (62.58) | 114 (48.51) | 0.006 |
| Respiratory | 60 (25.32) | 47 (29.19) | 0.392 | 42 (25.77) | 65 (27.66) | 0.675 |
| Neurological | 28 (11.81) | 24 (14.91) | 0.369 | 15 (9.20) | 37 (15.74) | 0.057 |
| Pain | 158 (66.67) | 107 (66.46) | 0.966 | 106 (65.03) | 159 (67.66) | 0.585 |
| Psychotropic Drug Intake (D) | 0.071 | 0.018 | ||||
| C | 100 (47.17) | 46 (34.07) | 60 (41.67) | 86 (42.36) | ||
| AD | 62 (29.25) | 43 (31.85) | 55 (38.19) | 50 (24.63) | ||
| ADAC | 24 (11.32) | 16 (11.85) | 15 (10.42) | 25 (12.32) | ||
| ADAP | 13 (6.13) | 15 (11.11) | 8 (5.56) | 20 (9.85) | ||
| ADACP | 13 (6.13) | 15 (11.11) | 6 (4.17) | 22 (10.84) | ||
| Other Psychotropic Drug Intake | ||||||
| Benzodiazepines | 53 (22.65) | 35 (22.01) | 0.882 | 25 (15.63) | 63 (27.04) | 0.008 |
| Hypnotics | 15 (6.41) | 16 (10.06) | 0.187 | 15 (9.38) | 16 (6.87) | 0.365 |
| Wellbutrin | 21 (8.97) | 13 (8.18) | 0.782 | 18 (11.25) | 16 (6.87) | 0.129 |
| Trazodone | 35 (14.96) | 17 (10.69) | 0.221 | 18 (11.25) | 34 (14.59) | 0.337 |
| Mirtazapine | 8 (3.42) | 6 (3.77) | 0.852 | 6 (3.75) | 8 (3.43) | 0.868 |
| Lithium | 9 (3.85) | 1 (0.63) | 0.054a | 3 (1.88) | 7 (3.00) | 0.746a |
| Opiates | 31 (13.25) | 25 (15.72) | 0.491 | 26 (16.25) | 30 (12.88) | 0.347 |
| Antihistamines | 46 (19.66) | 24 (15.09) | 0.246 | 27 (16.88) | 43 (18.45) | 0.688 |
Mann-Whitney test was used for the analyses of continuous variables. Pearson’s Chi-Square test was used for the analyses of categorical variables, except where marked with a, which refers to the use of Fisher’s exact test.
AHI: apnea-hypopnea index; PLMI: periodic limb movement index; N: count; P: valid percent; SD: standard deviation; NC: neck circumference; BMI: body mass index; ESS: Epworth sleepiness scale; C: controls group; AD: antidepressants group; ADAC: antidepressants and anticonvulsants; ADAP: antidepressants and antipsychotics; ADACP: antidepressants and anticonvulsants and antipsychotics group